Sartorius, DE0007165631

Barclays raises target for Sartorius stock to EUR 310

Published on 10/07/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock costs EUR 258.45 on October 7, 2026 after EUR 262.25. Second-quarter revenue rose 3.11 percent to EUR 911.8 million.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern
Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) was trading at EUR 258.45 at Lang & Schwarz on October 7, 2026 at 9:22 a.m. CEST, down 1.45 percent from the prior close of EUR 262.25. On September 30, 2026, Barclays raised its price target from EUR 300.00 to EUR 310.00 and kept its Overweight rating, according to FinanzNachrichten.

Barclays sees mid-range guidance

Barclays analyst Charles Pitman-King expects Sartorius to place its annual targets in the middle of the companys guidance corridor ahead of the third-quarter report. The target change gives the stock 19.96 percent upside from the Lang & Schwarz price, calculated against the EUR 310.00 target.

The rating comes as investors prepare for the next operating update. The companys investor-relations page identifies the third-quarter report as the next key reporting event on October 22, 2026, while its fiscal 2026 outlook calls for constant-currency sales growth of 5 percent to 9 percent and an underlying EBITDA margin slightly above 30 percent, according to Sartorius.

Revenue growth meets a tougher test

Sartorius reported revenue of EUR 911.8 million in the second quarter of 2026, an increase of 3.11 percent from the comparable period, according to Parqet. Net profit reached EUR 41.2 million, up 26.77 percent year over year, while EBITDA was EUR 281.2 million, up 19.91 percent.

The comparison explains why the October report matters more than the target revision alone. Barclays is looking for execution within the existing corridor, while the second-quarter figures show profit growth running ahead of revenue growth. That mix leaves the margin trajectory and equipment demand as the most important tests for the next update.

Stock stays below the new target

JPMorgan also kept an Overweight rating and a EUR 295.00 target on September 27, 2026, with analyst Richard Vosser expecting Sartorius to slightly exceed third-quarter expectations, according to Finanzen.at. The separate EUR 295.00 target is 14.15 percent above the Lang & Schwarz price and provides a lower comparison point than Barclays EUR 310.00 target.

At Lang & Schwarz, Sartorius was trading at EUR 258.45 on October 7, 2026 at 9:22 a.m. CEST, down 1.45 percent versus the prior close of EUR 262.25. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.

Sartorius stock facts

  • Company: Sartorius AG
  • ISIN: DE0007165631
  • WKN: 716563
  • Ticker: SRT3
  • Primary exchange: Xetra
  • Price Lang & Schwarz as of October 7, 2026, 9:22 a.m. CEST: EUR 258.45
  • Change versus prior close: minus 1.45 percent
  • Prior close Lang & Schwarz October 6, 2026: EUR 262.25
  • Sector / Industry: Health Care / Health Care Equipment and Supplies
  • Index membership: MDAX
  • Next earnings date: October 22, 2026

More news and analyses on Sartorius stock

Disclaimer...

en | DE0007165631 | SARTORIUS | boerse | 70253194 | bgmi